Nautilus Biotechnology Inc (NAUT) gets rating Downgrade from Goldman

Daniel Torres

Nautilus Biotechnology Inc’s filing revealed that its Chief Marketing Officer Suzuki Kentaro acquired Company’s shares for reported $5960.0 on Nov 06 ’25. In the deal valued at $1.49 per share,4,000 shares were bought. As a result of this transaction, Suzuki Kentaro now holds 4,000 shares worth roughly $6640.0.

Then, Patel Sujal M bought 116,500 shares, generating $78,544 in total proceeds. Upon buying the shares at $0.67, the CEO, President, and Secretary now owns 10,258,221 shares.

Before that, Patel Sujal M bought 83,500 shares. Nautilus Biotechnology Inc shares valued at $57,031 were divested by the CEO, President, and Secretary at a price of $0.68 per share. As a result of the transaction, Patel Sujal M now holds 10,341,721 shares, worth roughly $17.17 million.

Goldman downgraded its Nautilus Biotechnology Inc [NAUT] rating to a Sell from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Morgan Stanley started covering the stock on January 06, 2022. It rated NAUT as “an Equal-weight”.

Price Performance Review of NAUT

On Tuesday, Nautilus Biotechnology Inc [NASDAQ:NAUT] saw its stock unchanged to $1.66. Over the last five days, the stock has gained 4.40%. Nautilus Biotechnology Inc shares have fallen nearly -37.59% since the year began. Nevertheless, the stocks have fallen -1.19% over the past one year. While a 52-week high of $2.67 was reached on 01/21/25, a 52-week low of $0.62 was recorded on 09/04/25.

Levels Of Support And Resistance For NAUT Stock

The 24-hour chart illustrates a support level at 1.5967, which if violated will result in even more drops to 1.5333. On the upside, there is a resistance level at 1.7317. A further resistance level may holdings at 1.8033.

How much short interest is there in Nautilus Biotechnology Inc?

A steep rise in short interest was recorded in Nautilus Biotechnology Inc stocks on 2025-10-31, dropping by 4040.0 shares to a total of 0.18 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 0.19 million shares. There was a decline of -2.19%, which implies that there is a negative sentiment for the stock.

The most recent change occurred on November 02, 2021 when Cowen began covering the stock and recommended ‘”an Outperform”‘ rating.

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.